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Natural killer (NK) cell immunotherapy as a cancer treatment shows promise, but expanding NK cells
consistently from a small fraction (w5%) of peripheral blood mononuclear cells (PBMCs) to therapeutic
amounts remains challenging. Most current ex vivo expansion methods use co-culture with feeder cells (FC),
but their use poses challenges for wide clinical application. We developed a particle-based NK cell expansion
technology that uses plasma membrane particles (PM-particles) derived from K562-mbIL15-41BBL FCs. These
PM-particles induce selective expansion of NK cells from unsorted PBMCs, with NK cells increasing 250-fold
(median, 35; 10 donors; range, 94 to 1492) after 14 days of culture and up to 1265-fold (n ¼ 14; range, 280 to
4426) typically after 17 days. The rate and efﬁciency of NK cell expansions with PM-particles and live FCs are
comparable and far better than stimulation with soluble 41BBL, IL-15, and IL-2. Furthermore, NK cells expand
selectively with PM-particles to 86% (median, 35; range, 71% to 99%) of total cells after 14 days. The extent of
NK cell expansion and cell content was PM-particle concentration dependent. These NK cells were highly
cytotoxic against several leukemic cell lines and also against patient acute myelogenous leukemia blasts.
Phenotype analysis of these PM-particleeexpanded NK cells was consistent with an activated cytotoxic
phenotype. This novel NK cell expansion methodology has promising clinical therapeutic implications.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Much excitement has surrounded the possibility of using
natural killer (NK) cells for anticancer immunotherapy [1].
NK cells were discovered in the 1960s [2] and were later
found to be cytotoxic toward cancerous cells or cells infected
by viruses [3]. NK cells selectively target tumor cells lacking
MHC class I whereby lack of inhibitory interaction with MHC
class I and engagement of activating receptors by ligands,
preferentially expressed on transformed cells, triggers NK
cells to release cytotoxic granules with perforin and gran-
zyme, which induce apoptosis of targets cells [4].edgments on page 639.
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ty for Blood and Marrow Transplantation.NK cell infusion is promising for cancer immunotherapy,
including acute myelogenous leukemia (AML). Several
clinical trials have been performed or are ongoing to test
safety and efﬁcacy of infused NK cells for antitumor therapy
[5,6]. In the largest trial so far, with partially puriﬁed hap-
loidentical NK cells infused into lymphodepleted patients,
30% of poor-prognosis AML patients reached remission,
although high IL-2 caused side effects and patients later
relapsed. This trial showed the safety of NK cell infusion and
that expansion of infused NK cells is possible, potentially
leading to remission without graft-versus-host disease
(GVHD) [7].
Although highly encouraging, more optimization is
necessary before NK cell immunotherapy can be widely
clinically applied. Broadly, there are 3 overlapping paths to-
ward optimizing NK cell immunotherapy: (1) activation of
NK cell cytotoxicity, both in vivo and ex vivo; (2) expansion of
NK cells, in vivo and ex vivo; and (3) direction of cytotoxicity
more speciﬁcally toward tumor cells.
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NK cells for clinical purposes. To attain therapeutically suf-
ﬁcient amount of NK cells, a combination of NK cell enrich-
ment and cytokine-based stimulation has been used. The
presence of T cells in the infused cell population leads to
GVHD. and therefore CD3þ T cells are depleted to yield
product enriched in NK cells to a purity of w50%. NK cell
puriﬁcation has been attempted by CD3 depletion followed
by CD56 enrichment to achieve 90% to 95% NK cells [6,8,9].
Overnight treatment of puriﬁed NK cells with IL-2 (500 to
1000 U/mL) signiﬁcantly activates their cytotoxicity. CD19þ B
cell depletion has also been appended to reduce passenger B
lymphocyteemediated complications [10].
The major challenge with NK cell immunotherapy has
been to obtain large numbers of NK cells to be an efﬁcacious
treatment. Several methods have been attempted for ex vivo
NK cell expansion. NK cells expand poorly (20-fold) when
stimulated with cytokines only. A combination of IL-2 (500
U/mL) and anti-CD3 antibodies yielded 70- to 200-fold
expansion with 10% to 80% NK cell purity with a signiﬁcant
number of T and/or NKT cells [11,12]. NK cell expansion from
peripheral blood mononuclear cells (PBMCs) derived from
myeloma patients were also performed, and NK cells
expanded an average of 1,600-fold in medium containing IL-
2 (500 U/mL) and initial OKT3 [13]. These protocols have
signiﬁcant downsides, such as the use of a high concentra-
tion of IL-2 in culture, which can lead to short persistence of
NK cells upon cytokine withdrawal after infusion, and low
NK cell purity, which in allogeneic settings requires further
manipulations to remove T cells [14].
NK cells have also been expanded using feeder cells
(FCs) in culture. Irradiated PBMCs can be used as FCs to
expand enriched NK cells by 200- to 400-fold. Childs et al.
expanded puriﬁed NK cells by co-culturing with Epstein-Barr
virusetransformed lymphoblastoid cell lines [15]. The NK
cells expand about 1000-fold with relatively high IL-2 [15]. A
chronicmyelogenous leukemia (CML) cell line, K562, has been
engineered to express NK cellestimulating molecules, IL-15
and 41BBL, on the cell surface. Culturing K562-mb15-41BBL
with unselected PBMCs yields a median expansion of 152-fold
in 24 days and 277-fold NK cell expansion after 21 days [16].
This method uses low concentrations of IL-2 and yields NK
cells with low T cell contamination (w5% to 65%). These
expansion methods are well summarized in a review [17].
Although recent advances in NK cell expansion using FCs
are effective, such methodologies have drawbacks. First, use
of K562 variants or Epstein-Barr virusetransformed lym-
phoblastoid cell lines implies a possibility that tumor-
derived FCs or their genetic material may be injected into a
patient. Although methodologies such as irradiation of FCs
and other safeguards have been implemented by production
centers, the possibility cannot be completely negated. Sec-
ond, co-culture systems are highly complex and more vari-
able. Such a system necessitates additional time to culture
the stimulator cells and also requires a larger culture volume
to support metabolic activity of FCs. Also, additional testing
of the ﬁnal product is required before release to ensure the
lack of live FCs [18].
Here we explore a novel NK cell expansion method that
does not require co-culturing with live FCs, which would
completely negate the possibility of live tumor-derived
cells being injected into a patient, and that could be
adapted to rely on “off-the-shelf” reagents. Because the NK
cellestimulating molecules are present on the cell surface
of engineered K562-mb15-41BBL cells, membranepreparations from the cells would be capable of stimulating
expansion of NK cells. Such a FC-free methodology could be
capable of stimulating NK cells to expand and to be cyto-
toxic, similar to FC-based expansion, while avoiding the
drawbacks associated with the use of live FCs for NK cell
expansion. More importantly, this method of NK cell
stimulation may be transferrable to an in vivo setting for
NK cell expansion in vivo.
METHODS
Human Samples
Primary leukemia blasts were obtained from peripheral blood of pa-
tients with active disease who signed an institutional review board-
eapproved informed consent. Peripheral blood from leukemia patients or a
leukocyte source (One Blood, Orlando, FL) was mixed 1:2 with RPMI 1640,
overlaid on Ficoll-Paque (GE Healthcare, Pittsburgh, PA), and centrifuged
(600 g, 25 minutes). The PBMC layer was collected, cells washed twice by
centrifugation (200 g, 8 minutes), followed by resuspension in RPMI 1640.
Isolated PBMCs were then either cultured or frozen in stem cell growth
media (SCGM, CellGenix, Portsmouth, NH) supplemented with 10% FBS and
5% DMSO. All samples were deidentiﬁed.
Reagents and Cell Lines
K562, KG-1, HL-60, and BDCM cell lines were from ATCC (Manassas, VA).
K562-mb15-41BBL was kindly provided by Dario Campana of St. Jude Chil-
dren’s Research Hospital. PanToxiLux cytotoxicity assay was purchased from
OncoImmunin (Gaithersburg, MD), whereas V450 Annexin V was from BD
Biosciences (Sparks, MD). Enumeration Flow-Count beads were purchased
from Beckman Coulter (Miami, FL). The following dye conjugated antibodies
were used for phenotyping: anti-CD11b-PC7, anti-CD94-APC, anti-CD16-
FITC, anti-CD11a-FITC, anti-NKp46-PE, anti-NKG2A-PE, anti-CD244-PerCP-
Cy5.5, anti-CD7-PC7, anti-CD56-PC7, anti-CD3-APC, and anti-NKG2D-APC
(all from Beckman Coulter); anti-CD3-eFluor450, anti-CD3-Alexa 488,
anti-FasL-PE, anti-CD62L-PC7, anti-CD11b-APC, anti-CD56-APC-eFluor780,
and anti-CD3APC-eFluor780 (all from eBiosciences San Diego, CA); anti-
CD56-PE and anti-KIR2D-APC (both from Miltenyi Biotech San Diego, CA);
and anti-NKp30-Alexa488, anti-TRAIL-PE, anti-NKG2C-PE, and anti-NKp44-
APC (all from R&D Systems Minneapolis, MD).
Preparation and Characterization of Plasma Membrane Vesicles
K562-mb15-41BBL cells were grown in RPMI-1640 media supple-
mented with 5% FBS. Cells were harvested by centrifugation (1000 g, 10
minutes) and washed with Dulbecco’s PBS containing 2 mM EDTA. Cells
were resuspended in lysis buffer containing 50 mM HEPES, pH 7.4, 150 mM
NaCl, 2 mM MgCl2 and AEBSF, aprotinin, leupeptin, and pepstatin A. Cells
were disrupted by nitrogen cavitation at 300 psi for 30 minutes at 4C (Parr
Instruments, Moline, IL). Cell lysate was centrifuged (1000 g, 10 minutes)
and the supernatant then centrifuged (100,000 g) to pellet the crude cell
membranes. The crude membranes were further puriﬁed by sucrose
gradient centrifugation, and the fraction that corresponds to closed plasma
particles vesicles was collected [19].
All procedures were performed using aseptic techniques, and sterility of
the product was tested in culture. The protein content of the plasma
membrane (PM) preparations was quantiﬁed by BCA assay and speciﬁed as
mg membrane protein/mL [20]. The presence of 41BBL and IL-15 proteins on
pure PM-particles was conﬁrmed by ELISA, Western Blot, and ﬂow cyto-
metric detection on 5 mm Latex beads [21].
NK Cell Expansion from PBMCs
PBMCs were seeded at .1  106 NK cells/mL in SCGM (CellGenix, Ports-
mouth, NH) supplemented with 10% FBS, 2 mMGlutamax, and 50 U/mL IL-2
(Peprotech, Rocky Hill, NJ). NK cell growth was stimulated with either PM-
particles at indicated concentrations or 1  106 K562-mb15-41BBL cells
pretreated with mitomycin C (50 mg/mL) to stop their proliferation [22].
Control conditions received soluble IL-15 (50 ng/mL) and 41BBL (50 ng/mL)
(both fromPeprotech).Half themediawas replaced every 2 to3 days. Ondays
7 and 14, cells were centrifuged (500g, 5 minutes) and four-ﬁfth volume of
themediawas replaced toavoidpotential accumulationof byproducts aswell
as to provide nutrients to rapidly dividing NK cells. Because PM-particles and
soluble cytokines do not pellet with the cells while FCs are obliterated by NK
cell, they were all resupplemented with the media replacement step. Cell
contentwasmonitored bystainingwith anti-CD56-PE and anti-CD3-APC and
analyzing on a C6 Accuri cytometer (BD Biosciences).
Determination of NK Cell Phenotype
Unexpanded NK cells or NK cells expanded by either 200 mg/mL PM-
mb15-41BBL particles or K562-mb15-41BBL cells for 14 to 21 days were
AB
Figure 1. PM-mb15-41BBL particles cause expansion of NK cells efﬁciently
and selectively and in a concentration-dependent manner. PBMCs were
stimulated with 50 U/mL IL-2 and PM-mb15-41BBL particles at 0 to 800 mg of
membrane protein/mL for 21 days. The fold of NK cell expansion (A) and the
NK cell content as a percentage of total live cells (B) over the culture time are
plotted for the following PM-particle concentrations: 0 (C), 25 (-), 50 (:),
100 (;), 200 (A), 400 (B), and 800 (,). Each data point represents an
average of 2 replicates, with the error bar representing a standard deviation.
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and Cell Lines, above) in Dulbecco’s PBS, 2 mM EDTA, and .5% BSA. Cells were
washed with the same buffer and analyzed on a Canto II (BD Biosciences).
CompBeads (BD Biosciences) were used to determine compensation for each
antibody panel. Data were analyzed with FlowJo software (TreeStar, http://
www.ﬂowjo.com/).
Cytotoxicity of Fresh and Expanded NK Cells
Cytotoxicity of NK cells was assayed by either granzyme or annexin V23
assay using K562, KG1, HL-60, or BDCM or primary leukemia blasts from
PBMCs as targets for the granzyme assay, target cells (10  106 cells) were
labeled with TFL4, supplied with the PantoxiLux assay (OncoImmunin), in 1
mL of RPMI 1640 for 15 minutes at room temperature. Cells were washed 3
times with RPMI 1640 with 20% FBS. Target cells at .5  106 cells/mL were
mixed with NK cells at effector to target ratios (E:T) of .3:1 to 2:1 and
incubated for 1.5 hours at 37C, 5% CO2 atmosphere. Cells were centrifuged,
resuspended in granzyme substrate, labeled with anti-CD56-PE, and incu-
bated (30 minutes at room temperature). The cell mixture was then
analyzed on a Canto II (BD Biosciences).
For the annexin V assay, targets labeled similarly as in the granzyme
assay were mixed at .5106 cells/mL with NK cells at E:T ratios of .5:1 to 5:1
and incubated (4 hours, 37C, 5% CO2 atmosphere). Cells were centrifuged
and resuspended in annexin V labeling buffer (BD Biosciences) with V450
annexin V, anti-CD16-FITC, and anti-CD34-PC7; incubated (on ice, 15 mi-
nutes); and diluted to 400 mL. Flow-Count beads (Beckman-Coulter) were
used as internal reference and analyzed on a Canto II (BD Biosciences).
RESULTS
NK Cell Expansion by PM-Particles
The NK stimulatory ligands IL-15 and 41BBL on the K562-
mb15-41BBL cells are membrane surface bound, and there-
fore we hypothesized that closed PM vesicles derived from
membrane preparation from K562-mb15-41BBL cells will
stimulate expansion of NK cells. PM-particles from K562-
mb15-41BBL (denoted as PM-mb15-41BBL) were collected
from a sucrose density gradient at a density corresponding to
closed PM vesicles and were characterized for presence of IL-
15 and 41BBL by ELISA, Western blot, and ﬂow cytometry
(Table 1 and Supplemental Figure 1).
To test if PM-mb15-41BBL particles speciﬁcally induce NK
cell (PM-NK) expansion and to determine the optimal con-
centration for expansion, concentration of PM-mb15-41BBL
in PBMC/NK cell cultures were varied (0 to 800 mg/mL) and
cells cultured over 21 days (Figure 1). NK cell expansionwith
PM-mb15-41BBL was dependent on concentrations of PM-
mb15-41BBL, with an optimum of 200 mg/mL, which yiel-
ded 2200-fold NK cell expansion in 21 days. Concentrations
of PM-mb15-41BBL less than or greater than 200 mg/mL
resulted in lower levels of NK cell expansion and slower
expansion kinetics, with the effect being themost evident for
concentrations below 100 mg/mL or above 400 mg/mL. NK cell
enrichment was also dependent on PM-mb15-41BBL and
resulted in the NK cell consisting of 95% of the culture on the
day 21 at the optimal PM-particle concentration.
To compare the PM-particle expansion with the
conventional expansion using live K562-mb15-41BBL FCs,
unpuriﬁed PBMCs were cultured side-by-side with
PM-mb15-41BBL particles or K562-mb15-41BBL FCs for 21
days. NK cells stimulated with PM-mb15-41BBL particles
(denoted PM-NK) expanded 572-fold (Figure 2A-), whereas
NK cells simulated with K562-mb15-41BBL feedersTable 1
PM Preparation
Yield (mg PM
Protein/g Cell Pellet)
PM Concentration
(mg PM/mL)
mbIL-15 (ng/mg
PM Protein)
Median 1.7 (.5-2.9) 10 (5-16) 14 (12.5-15.3)
Mean 1.6  .7 10  3 14  1
N 16 16 4expanded 396-fold (Figure 2A B) by day 16 of culture. The
rate and overall extent of expansion with PM-particles was
comparable with NK cell expansion with K562-mb15-41BBL
FCs (denoted FC-NK) and signiﬁcantly better than with just
soluble cytokines. Expansion of PM-NK cells was effective
from 10 different sources of PBMCs and also with multiple
preparations of PM-mb15-41BBL particles (Figure 2B). Based
on cumulative analysis of 35 expansions using 10 different
PBMC sources, median fold of expansion was 250-fold (n ¼
35; range, 94 to 1492) over 13  1 days (Figure 2B) with
median maximal expansion of 1265-fold (n ¼ 14; range, 280
to 4426), whichwas typically achieved by day 17. This level of
expansion is 2 orders of magnitude greater than with
cytokines (data not shown) and comparable with the re-
portedmedian expansion of 152 (range, 70 to 744; n¼ 5; day
14) for FC-NK on day 14 with median maximal expansion of
27,716. Furthermore, the PM-particles (pure PM vesicle
fractions) were much more effective at NK cell expansion
than crude PMs (40- to 50-fold NK cell expansion with crude
PMs after 14 days). Importantly, the stimulus for expansion is
speciﬁc for NK cells, with NK cell content rising from initial
<10% to over>70% in 14 days andmaintained at92% out to
3 weeks (Figure 2C). The content of T, NKT, and B cells
decreased during the culture to constitute 5%, 0%, and 0%,
respectively, at the end of culture period. Based on cumula-
tive analysis of 35 expansions from 10 different donors, the
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Figure 2. PM-mb15-41BBL particles stimulate selective NK cells expansion as effectively as FCs. (A) Expansion of NK cells from PBMCs were stimulated with 200 mg
membrane protein/mL PM-mb15-41BBL particles (-) or co-cultured with K562-mb15-41BBL FCs (B) for 21 days. Control wells received soluble cytokines IL-2 alone
at 50 U/mL () or IL-2 in combination with IL-15 at 50 ng/mL and 41BBL at 50 ng/mL (þ). The cell content was analyzed every 2 to 3 days and media exchanged as
needed. One representative expansion is depicted out of 35 performed with PBMCs derived from 10 different donors. Each point represents average of duplicate
cultures. (B) Cumulative analysis of NK cell expansion induced by stimulation of PBMCs derived from 10 donors with PM-particles (200 mg/mL membrane protein).
Plotted are results for NK cell expansion on day 13  1 (n ¼ 35) and maximal expansion (n ¼ 14) typically observed on or after day 17. (C) NK cells (CD56þ CD3) were
selectively expanded from PBMCs stimulated with PM-mb15-41BBL particles (C), whereas the percent of CD56 CD3þ T cells (-), CD56þ CD3þ NKT cells (:), and
CD19þ B cells (A) decreased over the period of 14 days of culture.
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the median T cell content was 9% (range, 2% to 29%), NKT cell
2% (range, 0% to 11%), and other CD3, CD56 cells (including
B cells) 4% (range, 1% to 12%).
The PM-particles can be prepared consistently (Table 1),
batch tested, and conveniently stored in ready-to-use
aliquots at 80C, potentially providing a quality “off-the-
shelf” reagent. To determine the batch-to-batch variability
between PM-particle preparations, the unpuriﬁed PBMCs
obtained from 2 different donors were cultured side-by-side
with PM-mb15-41BBL particles from 3 independent prepa-
rations. The expansions from the same PBMC source were
reproducible and very consistent across multiple batches of
PM-particle preparations (Supplemental Figure 2, top).
To determine if PM-particles retain their activity with long-
term storage, NK cells were expanded from the same cry-
opreserved PBMC source in February 2014 and October 2014
using PM-particles prepared in June 2013 (Supplemental
Figure 2, bottom, squares) or were expanded in May 2013
and in October 2014 using PM-particles prepared in March
2013 (Supplemental Figure 2, bottom, circles). Higher NK cell
expansions were achieved in October 2014, most likely as a
result of reﬁnement of the PM-particle expansion method-
ology over the past 2 years, demonstrating no change in PM-
particle activity for at least 1 year with proper storage. To
address scalability, NK cells (.5  106) were cultured from
PBMCs using PM-particles and transferred on each step to alarger ﬂask to allow for increase in culture volume
(Supplemental Figure 3). NK cells were expanded to 50  106
and consisted of 85% of the ﬁnal culture. These data indicate
that the PM-particle methodology can be applied to large-
scale expansion and the scale-up procedure could be
further optimized.PM-NK Cells Are Highly Cytotoxic
An alternative NK cell expansion method is innovative,
but expanded NK cells need to be cytotoxic toward tumors.
Cytotoxicity of PM-NK cells was assayed by 2 ﬂow cytome-
tryebased methods to detect phosphatidylserine [23] or
granzyme [24] activity in apoptotic target cells. The cyto-
toxicity of PM-NK cells expanded for 14 days to >90% cell
content was measured with the annexin V assay against
targets at varying E:T ratios (.5:1 to 5:1). PM-NK cells were
cytotoxic against all targets tested, where half the targets
were lysed at an E:T ratio of .5:1 (Figure 3). As the E:T ratio
increased, cytotoxicity increased against all 3 target leuke-
mia cell lines and about 90% of K562 cells were annexin V
positive at an E:T ratio of 5:1. Cytotoxic activities of PM-NK
were next directly compared with fresh NK cells isolated
from the same PBMC source and preactivated overnight with
IL-2 (1000 U/mL) using granzyme B assay (Supplemental
Figure 4). PM-NK cells were 2 to 6 times more cytotoxic
than freshly isolated NK cells.
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Figure 3. NK cells expanded by PM-mb15-41BBL particles are highly cytotoxic
toward AML and CML cell lines. The cytotoxicity of NK cells expanded and
activated with PM-mb15-41BBL particles is shown against K562 CML cells (C),
KG1 AML cells (-), and HL-60 AML cells (:). Cytotoxicity is assessed with
increasing ratio (E:T ratio) of the effector NK cells with a ﬁxed number of
target tumor cells. The target cells and effector NK cells were incubated
together for 4 hours, and cytotoxicity was assessed by quantifying lysed target
cells by ﬂow cytometry based detection for V450 annexin V staining. Shown is
a representative ﬁgure from 3 experiments. Each data point represents an
average of duplicates, with an error bar representing standard deviation.
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directly compared using granzyme B assay. Expanded NK
cells were incubated with target cells at varying ratios. In all
cases, cytotoxicity, representing a percentage of targets with
granzyme B activity, increased with higher E:T ratios
(Figure 4). Moreover, PM-NK cells had slightly higher cyto-
toxicity against AML cells, whereas cytotoxicity against CML-
derived K562 cells was lower at the higher E:T ratio. This
experiment showed that PM-NK cells are at least as cytotoxic
or more cytotoxic than FC-NK cells.
Cytotoxicity of expanded PM-NK (Figure 5,C) or FC-NK
cells (Figure 5, ,) was further assessed against primary
leukemia cells from 3 AML patients using the annexin V
assay with inclusion of anti-CD34 to discriminate healthy
cells and AML blasts. The samples had 81%  5%, 82%  5%,
and 68%  3% CD34þ targets in the F026, M035, and M036
samples, respectively. Expanded NK cells had signiﬁcant
cytotoxicity toward patient AML cells that increased with
higher E:T ratios. Signiﬁcantly, PM-NK cells appeared to have
w20% higher cytotoxicity, even though NK cells were
expanded from the same PBMC source. Analysis of ﬂow
cytometry data used a gating strategy to segregate the TFL4
stained target population into CD34 nontumor and CD34þ
tumor cells (Supplemental Figure 5).
PM-Particle Expanded NK Cells Have Phenotypes
Indicating High Cytotoxic Potential
Overall, cytotoxicity and potential antitumor efﬁcacy of
NK cells depend on the balance of activating and inhibitory
signals. Thus, expression of 8 activating receptors, 3 inhibi-
tory receptors, 3 adhesion receptors, and death ligands was
analyzed on CD56þ/CD3 NK cells population (Figure 6 and
Supplemental Figure 6A-D). For each marker, difference of
the mean ﬂorescence intensity (DMFI) between using the
speciﬁc dye-conjugated antibody and the isotype was then
normalized with respect to the nonexpanded NK cells foreither PM-NK or FC-NK cells. The normalized DMFIs were
plotted for PM-NK cells (-) in comparison with FC-NK cells
(,), where values greater than 1 indicate higher expression
in expanded NK cells compared with unexpanded cells
(Figure 6).
PM-NK cells were very bright for CD56 compared with
unexpanded CD56dim populations (Supplemental Figure 7).
Generally, PM-NK cells were in an activated cytotoxic state.
Although levels of markers on PM-NK cells and FC-NK cells
were similar, there were key differences that may be
responsible for the somewhat higher cytotoxicity in PM-NK
cells. NKG2D, NKG2C, and NKp80 are type II trans-
membrane C-type lectin-like receptors, important for anti-
tumor immunosurveillance [25]. Both types of expanded NK
cells had a 3.5-fold higher expression of NKG2D compared
with unexpanded cells. The NKG2C expression was slightly
elevated for both types of expanded NK cells compared with
unexpanded NK cells. NKp80 was well expressed in all types
of NK cells. NKp30, NKp44, and NKp46 are activating natural
cytotoxicity receptors on NK cells that recognize heparin
sulfate on cancer cells and are important for tumor targeting
[26]. NKp30, NKp44, and NKp46 were moderately expressed
on unexpanded NK cells and increased after expansion. In
particular, NKp44, which mediates non-MHC restricted
killing, dramatically increased 4- and 10-fold for FC-NK cells
and PM-NK cells, respectively. CD244 (2B4/slamf4) is a
member of the signaling lymphocyte activation molecule
family [27]. PM-NK cells had 1.5-fold higher expression of
CD244 compared with unexpanded cells. CD16 on NK cells
binds the Fc portion of IgG to engage antibody dependent
cell-mediated cytotoxicity. As compared with unexpanded
NK cells, MFI for anti-CD16 decreased by 25% for both
expanded NK cells. A decrease of CD16 was previously
observed for NK cells stimulated with K562-mb15-41BBL FCs
and has been attributed to proteolytic activity of ADAM17
[28-30].
Killer cell immunoglobulin-like receptors (KIRs) signal to
inhibit cytotoxicity when bound to MHC class I molecules
[31]. KIR2D was increased on expanded NK cells compared
with unexpanded NK cells. However, the ﬂuorescence his-
togram for PM-NK cells revealed a signiﬁcant population
having lower expression. Expression of KIR2DL5 increased
marginally for the expanded NK cells. NKG2A is another type
II transmembrane protein and is a paralog to NKG2C.
Although both NKG2A and NKG2C complex to CD94, the
NKG2C interaction is activating, whereas signaling via
NKG2A is inhibitory. NK cells expanded by eithermethod had
an increased MFI for NKG2A compared with unexpanded
cells, but the increase in PM-NK cells (DMFI ¼ 380) is rela-
tively lower than the increase in FC-NK cells (DMFI ¼ 510).
Expression changes for adhesion receptors CD11a, CD11b,
and CD62L are similar between PM-NK and FC-NK cells.
Notably, the amount of CD62L, important for marrow hom-
ing, is comparable with unexpanded NK cells. However, FC-
NK cells appear to have a subpopulation of cells with
signiﬁcantly higher expression of CD62L, which was lacking
for PM-NK cells. The overall lower level of CD62L expression
in the PM-NK cells compared with FC-NK cells may be due to
cytokine-induced activity of ADAM17, previously reported
for NK cells activating with K562 FCs [29,30].
Tumor necrosis factorerelated apoptosis-inducing ligand,
or TRAIL, and FasL (CD95L) are 2 “death ligands” that induce
tumor cell apoptosis. Expression of both death ligands was
increased in both types of expanded NK cells as compared
with unexpanded NK cells.
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Figure 4. NK cells expanded by PM-mb15-41BBL particles are as cytotoxic or more cytotoxic than FC expanded NK cells toward AML and CML cell lines. The
cytotoxicity of NK cells expanded and activated with PM-mb15-41BBL particles (,) were directly compared with those co-cultured with mitomycin treated K562-
mb15-41BBL cells (C). Shown are comparative cytotoxicity against K562 CML cells (A), KG1 AML cells (B), HL-60 AML cells (C), and BDCM cells (D). Cytotoxicity is
assessed with increasing ratio (E:T ratio) of the effector NK cells with a ﬁxed number of target tumor cells. The target cells and effector NK cells were incubated
together for 1.5 hours, and cytotoxicity was assessed by quantifying lysed target cells by ﬂow cytometryebased detection of granzyme activity associated with tumor
targets. Each data point represents an average of 2 data points, with the error bar representing a standard deviation.
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PM-mb15-41BBL Particles Effectively Expand and
Activate NK Cells
A novel clinically applicable method for NK cell expansion
is likely to positively impact the progress of adoptive cellular
therapy. Several methods for clinical NK cell expansion have0.5
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Figure 5. NK cells expanded by PM-mb15-41BBL particles are highly cytotoxic toward
NK cells expanded using PM-mb15-41BBL particles (C) and those expanded by cultu
derived samples, F026 (A), M035 (B), and M036 (C), were used for the experiment. Cyto
a ﬁxed number of target tumor cells. The target cells and effector NK cells were incu
target cells with ﬂow cytometry based detection for V450 annexin V staining.been developed, and some are used in clinical trials
[5,7,32,33]. Current methods that yield sufﬁcient NK cells
and use relatively low IL-2 (200 U/mL) rely on co-culture
with feeder/stimulator cells. The method described herein
is distinct because it does not require exogenous live FCs and
could be performed with “off-the-shelf” reagents. Thus, this3:1 5:1
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AML patient-derived samples. The cytotoxicity against AML patient samples of
ring with mitomycin treated FCs (,) are shown. Three different AML patient-
toxicity is assessed with increasing ratio (E:T ratio) of the effector NK cells with
bated together for 4 hours and cytotoxicity was assessed by quantifying lysed
Figure 6. Phenotypic marker expression analysis shows that NK cells
expanded by PM-mb15-41BBL particles are activated. PM-mb15-41BBL parti-
cle expanded NK cells were analyzed for presence of 8 activating receptors, 3
inhibitory receptors, 3 adhesion receptors, and 2 “death receptor” ligands. MFI
values for speciﬁc antibody ﬂuorophores and isotype controls were deter-
mined using FlowJo software for CD56þ/CD3 gated NK cells shown in
Supplemental Figure 5. Each MFI value is determined as a difference from the
isotype control. Relative differences in MFI (DMFI) from the unexpanded for
NK cells expanded with PM-mb15-41BBL particles (-) and with NK cells
expanded by co-culturing with live K562-mb15-41BBL (,) are shown. The
presence of each marker is analyzed by ﬂow cytometry on CD56þ/CD3 gated
population. For each protein marker, unexpanded PBMCs (left), NK cells
expanded with PM-mb15-41BBL particles (center), and NK cells expanded
with K562-mb15-41BBL FCs (right) are analyzed using the speciﬁc antibody
(shaded histogram) or isotype control antibody (unshaded histogram).
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and should be translatable into a clinical setting. The PM-
particles induced NK cell expansion by 250-fold in 14 days
and maximally to 12-fold in 21 days from unsorted PBMCs
with purity > 95% of CD56þ/CD3 NK cells. There is a small
amount of T cells (<5%) that could be depleted for very pure
NK cells, making it clinically applicable. Dose dependence of
PM-particles for NK expansion was clearly observed, where
200 mg/mL was optimal for the rate of expansion, NK cell
enrichment, and the maximum extent of expansion. Higher
concentrations of PM-particles resulted in less efﬁcient
expansion, and a cause for such behavior is currently unclear.
NK cells stimulated by PM-particles not only expand but
are highly cytotoxic toward AML and CML cell lines as well as
against patient tumor cells. The cytotoxicity of PM-NK cells
was slightly higher compared with FC-NK cells. For cyto-
toxicity toward patient-derived AML tumor cells, NK cells
were expanded from donors that are most likely mis-
matched, and therefore the cytotoxic response against
healthy cells is expected. However, data with the M035
sample show a distinctly different trend between nontumor
and tumor targets (Supplemental Figure 5). The difference is
more pronounced for PM-NK cells than for FC-NK cells. This
difference may be due to some haplotype matching between
patient-derived sample and expanded NK cells. Haplotype
matching and this gating strategy may be used to analyze
compatibility of particular NK cells and targets. This type of
testingmay be prudent because expanded NK cells are highly
cytotoxic and may potentially mediate GVHD.
Overall, NK cell cytotoxicity is a function of multiple
activating and inhibiting signals. Expression levels of most
markers are similar between PM-NK and FC-NK cells.
However, there is signiﬁcant higher expression of NKp44 inPM-NK cells, where overall MFI is higher by about 2.5-fold as
compared with FC-NK cells. Of note, CD16 was the marker
where most PM-NK cells expressed CD16, but another 20% of
the population did not (Supplemental Figure 8), which may
affect their ability to exert antibody dependent cell-mediated
cytotoxicity. CD16 expression on both PM-NK and FC-NK
cells was lower as compared with unexpanded NK cells.
This effect is likely due to IL-15 and has been previously
noted when using K562-mb15-41BBL for NK cell expansion
[29,30]. Another small but potentially important difference
was observed in the expression of CD62L on PM-NK cells that
was lower than on FC-NK but unchanged as compared with
unexpanded NK cells. Because CD62L has been implicated in
homing of NK cells to bone marrow, this may potentially
affect their in vivo efﬁcacy. Further, in vivo studies are
needed to determine homing of PM-NK cells. There also are
some minor differences for expression of inhibitory re-
ceptors by the different expanded NK cells. PM-NK cells have
a larger subpopulationwith a lower expression of KIR2D, and
the trend is reversed for the FC-NK cells. Overall, PM-NK cells
have a similar phenotype expression proﬁle as NK cell
markers compared with FC-NK cells that confers their rela-
tively high cytotoxicity.
These characteristics of PM-NK cells demonstrate that
cytokines or ligands bound in a particle can signal and
stimulate immune cells. The signaling mechanisms of
particle-bound IL-15 or 41BBL are likely to be similar to those
on K562-mb15-41BBL FCs and is evidenced by increased
expression of CD137 (4-1BB receptor) on expanded NK cells
(data not shown).
Toward Clinical Relevance of PM-Particle Expanded NK
Cells
Characteristics and NK cellestimulating attributes of PM-
mb15-41BBL may seem similar to K562-mb15-41BBL FCs.
However, several important technical and clinically relevant
differences make PM-particles more advantageous for NK
cell expansion. First, any method that relies on co-culture is
more complex and less predictable, making logistics more
challenging. Use of feeder/stimulator cells requires proper
banking of FCs under cGMP conditions and testing before
each culture with NK cells. On the other hand, PM-particles
can be produced, tested, packaged at a central cGMP facil-
ity, and shipped to a participating center, as is the case for
many “biologicals.” Second, total culture volume must be
greater for a culture with FCs due to K562 FCs consuming
nutrients, whereas PM-particles obviously do notmetabolize
nutrients. Although K562 FCs used in NK expansion are g-
irradiated, restricting cell division, FCs still conduct meta-
bolism and compete for nutrients. We conﬁrmed signiﬁcant
higher glucose consumption in FC co-cultures compared
with PM-particles (data not shown).
Third, although centers that use NK -stimulating K562 FCs
have release criteria, there is always some chance that FCs
may get injected into a patient. NK cell expansion method-
ology using PM-particles, prepared by differential centrifu-
gation, which completely separates PM-particles fromwhole
cells, does not provide such a chance. Fourth, NK cell growth
with FCs necessitates handling of 2 cultures with associated
contamination risks, whereas the PM-particles used for
expansion can be treated as a reagent in the freezer. In our
hands, PM-particles in freezer storage for several months
were just as effective for NK cell expansion (Supplemental
Figure 2). Fifth, the supernatant from NK cell culture has
been shown to induce HLA expression on K562-mb15-41BBL
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necessitate prior CD3 depletion [18]. PM-particles are
derived from K562-mb15-41BBL cells that were never
exposed to NK cells and should lack HLA expression, limiting
problematic T cell expansion. The ﬁrst 3 reasons are directly
relevant to NK cell expansion with FCs in currently ongoing
clinical trials. Finally, PM-particleestimulated in vitro
expansion of NK cells may possibly be adapted to a clinically
usable method for direct in vivo NK cell expansion.
CONCLUSION
An FC-free method has been developed for NK cell
expansion from unsorted PBMC populations, expanding NK
cells on average 1800  1200-fold over 17 days to 86%  11%
purity and with high cytotoxicity. Development of this
method for PM-particleedependent NK cell expansion from
unselected PBMCs is signiﬁcant toward full development of a
facile, clinically adaptable NK cell expansion methodology.
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